胺碘酮治疗重症室性心律失常患者的临床效果探索(1)
【摘 要】目的：探析重症室性心律失常患者采用胺碘酮治疗的临床效果。方法：通过随机数字表法将本院2018年3月～2019年6月收治的76例重症室性心律失常患者分为两组，对照组(n=38)采用利多卡因治疗，治疗组(n=38)采用胺碘酮治疗。对比两组治疗效果、心律失常发作频率与持续时间、心功能指标。结果：对照组总疗效为73.68%，低于治疗组的92.11%，有统计学意义(x2=4.5470，P<0.05);治疗组治疗后的左室舒张末期内径(LVEDD)为(36.32±1.20)mm、左室收缩末期内径(LVESD)为(49.14±2.33)mm，左室射血分数(LVEF)为(48.60±0.24)%，优于对照组的(43.25±1.51)mm、(59.41±2.10)mm和(37.20±0.35)%，有统计学价值(t=22.1487，P<0.05;t=20.1832，P<0.05;t=165.5952，P<0.05);治疗后对照组心律失常发作频率为(3.66±1.04)次/周，持续时间为(4.49±0.11)min，與治疗组的(2.33±1.22)次/周、(3.14±0.36)min对比存在显著差异性(t=5.1142，P<0.05;t=22.1076，P<0.05)。结论：胺碘酮用于重症室性心律失常患者中能提高疗效，控制疾病发作次数与时间，还能改善心功能，临床推广价值高。
, 百拇医药
【关键词】室性心律失常;治疗效果;胺碘酮;心功能指标
【中图分类号】R541.7 【文献标识码】A 【文章编号】1672-3783(2019)10-0064-01
【Abstract】Objective： To explore the clinical effect of amiodarone in the treatment of severe ventricular arrhythmia. Methods：76 patients with severe ventricular arrhythmia admitted to our hospital from March 2018 to June 2019 were divided into two groups by random number table. The control group (n=38) was treated with lidocaine and the treatment group (n=38) with amiodarone. The therapeutic effect， frequency and duration of arrhythmia attack and cardiac function indexes were compared between the two groups. Results：The total curative effect of the control group was 73.68%， lower than 92.11% of the treatment group， with statistical significance (x2=4.5470，P<0.05); the left ventricular end-diastolic diameter (LVEDD) of the treatment group was (36.32+1.20) mm， the left ventricular end-systolic diameter (LVESD) was (49.14+2.33) mm， and the left ventricular ejection fraction (LVEF) was (48.60+0.24) mm.) Compared with the control group (43.25+1.51) mm， (59.41+2.10) mm and (37.20+0.35)%， it had statistical value (t=22.1487，P<0.05; t=20.1832， P<0.05; t=165.5952， P<0.05); after treatment， the frequency of arrhythmia attack in the control group was (3.66+1.04) times/week， and the duration was (4.49+0.11) min， which was related to the treatment. There were significant differences between the treatment group (2.33+1.22) times per week and (3.14+0.36) minutes (t=5.1142，P<0.05;t=22.1076，P<0.05). Conclusion：Amiodarone used in patients with severe ventricular arrhythmia can improve the curative effect， control the number and time of disease onset， and improve cardiac function. It has high clinical value., 百拇医药(宋雷英 曹位平)
, 百拇医药
【关键词】室性心律失常;治疗效果;胺碘酮;心功能指标
【中图分类号】R541.7 【文献标识码】A 【文章编号】1672-3783(2019)10-0064-01
【Abstract】Objective： To explore the clinical effect of amiodarone in the treatment of severe ventricular arrhythmia. Methods：76 patients with severe ventricular arrhythmia admitted to our hospital from March 2018 to June 2019 were divided into two groups by random number table. The control group (n=38) was treated with lidocaine and the treatment group (n=38) with amiodarone. The therapeutic effect， frequency and duration of arrhythmia attack and cardiac function indexes were compared between the two groups. Results：The total curative effect of the control group was 73.68%， lower than 92.11% of the treatment group， with statistical significance (x2=4.5470，P<0.05); the left ventricular end-diastolic diameter (LVEDD) of the treatment group was (36.32+1.20) mm， the left ventricular end-systolic diameter (LVESD) was (49.14+2.33) mm， and the left ventricular ejection fraction (LVEF) was (48.60+0.24) mm.) Compared with the control group (43.25+1.51) mm， (59.41+2.10) mm and (37.20+0.35)%， it had statistical value (t=22.1487，P<0.05; t=20.1832， P<0.05; t=165.5952， P<0.05); after treatment， the frequency of arrhythmia attack in the control group was (3.66+1.04) times/week， and the duration was (4.49+0.11) min， which was related to the treatment. There were significant differences between the treatment group (2.33+1.22) times per week and (3.14+0.36) minutes (t=5.1142，P<0.05;t=22.1076，P<0.05). Conclusion：Amiodarone used in patients with severe ventricular arrhythmia can improve the curative effect， control the number and time of disease onset， and improve cardiac function. It has high clinical value., 百拇医药(宋雷英 曹位平)
参见：首页 > 医疗版 > 疾病专题 > 心血管科 > 心律失常